background
felin
infecti
periton
fip
consid
highli
fatal
natur
occur
form
although
cat
resist
diseas
experiment
infect
suggest
cat
natur
may
also
resist
develop
fip
face
infect
fip
viru
fipv
previou
experiment
fipv
infect
studi
suggest
role
cellmedi
immun
resist
develop
fip
experiment
fipv
infect
studi
specif
pathogen
free
spf
kitten
describ
longitudin
antivir
cell
respons
clinic
outcom
rang
rapid
progress
slow
progress
resist
diseas
result
differ
diseas
outcom
provid
opportun
investig
role
cell
immun
fip
determin
cell
subset
prolifer
stimul
differ
viral
antigen
reduc
total
white
blood
cell
wbc
lymphocyt
cell
count
blood
observ
primari
acut
infect
experiment
group
includ
cat
surviv
without
clinic
fip
antivir
cell
respons
earli
primari
infect
also
similar
cat
develop
fip
cat
remain
healthi
recoveri
antivir
cell
respons
later
phase
acut
infect
observ
subset
cat
surviv
longer
resist
diseas
compar
cat
show
rapid
diseas
progress
robust
cell
respons
termin
time
point
observ
lymph
node
compar
blood
cat
develop
fip
cat
surviv
primari
infect
challeng
second
time
pathogen
fipv
test
antivir
cell
respons
four
week
period
nine
ten
rechalleng
cat
develop
fip
cell
deplet
cat
demonstr
antivir
cell
respons
multipl
time
point
rechalleng
conclus
summari
definit
adapt
cell
respons
predict
diseas
outcom
detect
earli
phase
primari
fipv
infect
howev
emerg
antivir
cell
respons
second
exposur
fipv
implic
cellular
immun
control
fipv
infect
diseas
progress
viru
host
interact
earli
stage
fipv
infect
warrant
investig
elucid
host
resist
fip
natur
occur
felin
infecti
periton
fip
invari
fatal
clinic
sign
appear
howev
mortal
due
felin
infecti
periton
viru
fipv
infect
may
nearli
sever
report
field
indic
mani
infect
cat
may
show
overt
clinic
diseas
therefor
escap
diagnosi
proport
natur
infect
cat
resist
diseas
difficult
estim
although
probabl
similar
proport
random
bred
cat
fail
develop
fip
experiment
infect
depend
strain
fipv
rout
inocul
use
experiment
infect
random
bred
cat
resist
diseas
natur
immun
unknown
although
humor
immun
known
nonprotect
contributori
diseas
sign
multipl
studi
led
research
conclud
immun
fipv
larg
cellmedi
potenti
role
cellular
immun
fip
also
infer
experi
cat
render
immunocompromis
chronic
experimentallyinduc
felin
immunodefici
viru
fiv
infect
twenti
percent
fivinfect
cat
develop
fip
upon
infect
felin
enter
coronaviru
fecv
parent
viru
fipv
wherea
none
fiv
naiv
sibl
becam
ill
studi
suggest
although
fecv
fipv
mutat
quit
common
natur
fip
unlik
develop
older
cat
face
normal
tcell
immun
first
studi
report
virusspecif
immun
respons
cat
recurr
fipv
infect
reveal
multipl
epitop
within
spike
protein
encod
fipv
target
cell
howev
predomin
respons
observ
cell
particularli
cat
surviv
type
ii
infect
later
report
base
experiment
infect
type
ii
type
inocul
demonstr
express
interferongamma
antivir
cell
associ
resist
develop
fip
studi
also
identifi
multipl
epitop
encod
within
domain
viral
spike
protein
n
protein
associ
respons
resist
develop
fip
spite
studi
bodi
evid
suggest
import
virusspecif
cell
respons
resist
fipvassoci
diseas
remain
small
especi
pathogen
type
fipv
isol
given
type
fipv
common
felin
coronaviru
field
addit
studi
character
virusspecif
cellular
immun
respons
type
fipv
infect
seem
particularli
warrant
report
describ
character
antivir
cell
respons
multipl
cohort
cat
involv
experiment
fipv
infect
studi
one
group
cat
develop
fip
follow
experiment
primari
fipv
infect
diseas
distinguish
two
differ
outcom
includ
rapid
slow
progress
small
proport
cat
within
experiment
infect
studi
prove
resist
diseas
demonstr
third
possibl
outcom
primari
experiment
fipv
infect
cohort
cat
resist
develop
fip
primari
infect
reinocul
fipv
examin
resist
cellular
immun
respons
associ
secondari
viru
challeng
antivir
cell
respons
observ
differ
infect
outcom
compar
character
possibl
virusspecif
cell
immun
correl
resist
develop
fip
although
uniqu
antivir
cell
respons
earli
acut
infect
could
correl
resist
suscept
fip
differ
antivir
cell
respons
observ
primari
versu
rechalleng
exposur
fipv
specif
pathogenfre
spf
cat
obtain
breed
coloni
felin
nutrit
pet
care
center
school
veterinari
medicin
univers
california
davi
ca
anim
hous
maintain
accord
regul
guidelin
univers
california
davi
institut
anim
care
use
committe
uc
davi
iacuc
approv
number
viru
naiv
spf
cat
n
age
five
six
month
design
primari
infect
group
inocul
oronas
rout
tissuederiv
isol
experiment
cat
infect
field
viru
previous
describ
viru
inoculum
contain
semipurifi
cellfre
supernat
fine
ground
diseas
tissu
includ
omentum
cat
cat
receiv
inoculum
contain
ml
dilut
cellfre
suspens
prove
infecti
cat
base
occurr
diseas
andor
seroconvers
ten
fipvresist
cat
age
month
deriv
previou
experiment
infect
studi
design
survivor
confirm
primari
infect
infecti
rechalleng
use
similar
fipv
inocula
infect
rout
establish
rechalleng
infect
group
amount
time
elaps
primari
fipv
infect
rechalleng
vari
survivor
cat
cohort
one
subgroup
survivor
cohort
involv
six
cat
receiv
primari
inocul
oronas
rout
two
six
month
prior
rechalleng
four
six
cat
subgroup
includ
survivor
deriv
primari
infect
group
describ
within
report
second
subgroup
includ
four
cat
receiv
inocul
deliv
either
oronas
intraperiton
rout
month
prior
rechalleng
twelv
uninfect
healthi
spf
cat
age
five
six
month
serv
control
studi
cat
follow
preble
week
week
postinfect
pi
time
euthanasia
due
develop
fip
weekli
blood
sampl
collect
complet
blood
count
cbc
cell
count
virusspecif
cell
immun
respons
assay
inocul
cat
also
monitor
daili
rectal
temperatur
fever
inappet
depress
diarrhea
dehydr
ascit
hyperbilirubinuria
jaundic
cat
show
symptom
fip
euthanat
intraven
overdos
pentabarbitalphenytoin
mesenter
lymph
node
mln
peripher
lymph
node
pln
blood
peripher
blood
mononuclear
cell
pbmc
plasma
isol
collect
cat
undergo
euthanasia
due
onset
fip
two
healthi
uninfect
control
cat
experiment
cat
cohort
part
larger
experiment
infect
studi
test
fipv
pathogenesi
accord
differ
fipv
variant
prior
infect
either
fipv
fecv
cat
maintain
hous
free
felin
pathogen
care
uniform
manner
isol
pbmc
mononuclear
cell
lymph
node
pbmc
isol
blood
sampl
collect
infect
cat
weekli
time
point
densiti
centrifug
use
ficollhistopaqu
sigmaaldrich
st
loui
mo
mononuclear
cell
isol
lymph
node
tissu
lnmc
harvest
post
mortem
cat
develop
fip
previous
describ
pbmc
lnmc
incub
overnight
pbmc
media
without
interleukin
il
assay
cell
phenotyp
fipvspecif
cell
respons
follow
day
lymphocyt
cell
count
base
cell
frequenc
within
pbmc
prepar
determin
multicolor
flow
cytometri
total
lymphocyt
count
deriv
cbc
pbmc
assay
cell
frequenc
stain
either
biotinyl
alexa
fluor
af
antihuman
monoclon
antibodi
abd
serotec
raleigh
nc
specif
conserv
intracellular
epitop
shown
crossreact
multipl
speci
includ
felin
analysi
flow
cytometri
biotinyl
antibodystain
cell
detect
strepavidinphycoerythrin
pe
conjug
invitrogen
valencia
ca
viabil
cell
acquir
flow
cytometr
analysi
assess
use
live
fixabl
aqua
stain
invitrogen
data
acquir
use
lsrii
flow
cytomet
bd
bioscienc
san
diego
ca
event
obtain
sampl
analyz
use
flowjo
softwar
treestar
inc
ashland
serum
sampl
collect
fipvinocul
cat
uninfect
control
test
viral
antibodi
indirect
immunofluoresc
antibodi
ifa
assay
previous
describ
commerci
slide
coat
fipv
type
iiinfect
cell
vmrd
pullman
wa
assay
perform
accord
manufactur
recommend
dilut
slide
assay
use
fluoresc
microscopi
olympu
olympu
center
valley
pa
titer
report
base
highest
dilut
yield
detect
fluoresc
foci
infect
cell
two
differ
extract
method
use
nucleic
acid
extract
cell
tissu
studi
one
method
viral
nucleic
acid
extract
pbmc
use
rlt
lysi
buffer
qiagen
valencia
ca
beta
mercaptoethanol
per
manufactur
instruct
result
lysat
proteindigest
min
extract
rna
dna
util
commerci
kit
vetforal
qiagen
biosprint
magnet
bead
extract
qiagen
accord
manufactur
protocol
viral
rna
extract
plasma
also
util
rlt
lysi
buffer
rna
extract
use
qiaamp
viral
rna
mini
kit
qiagen
lnmc
mesenter
lymph
node
lyse
ab
lysi
buffer
appli
biosystem
grand
island
ny
rna
extract
perform
use
abi
prism
life
technolog
grand
island
ny
base
protocol
previous
describ
protocol
cdna
synthesi
previous
describ
fipv
viral
load
assay
plasma
pbmc
lnmc
mesenter
lymph
node
taqman
realtim
qpcr
use
primer
probe
set
base
conserv
felin
coronaviru
gene
minor
modif
publish
probe
set
sequenc
follow
agag
aagtttaaagatccgc
taqman
realtim
qpcr
perform
use
htfast
system
ab
taqman
realtim
qpcr
viral
rna
load
plasma
deriv
standard
curv
establish
plasmid
pcr
operon
contain
gene
target
sequenc
viru
load
pbmc
express
viral
rna
copi
per
million
pbmc
determin
normal
viral
copi
felin
chemokin
receptor
ccr
copi
number
measur
dna
extract
cell
prepar
base
standard
curv
establish
felin
coronaviru
felin
plasmid
detect
limit
either
viral
rna
dna
copi
per
reaction
viral
rna
load
lnmc
calcul
method
normal
viral
rna
express
felin
glyceraldehyd
dehydrogenas
gapdh
express
measur
lnmc
rna
sampl
panel
peptid
deriv
heptad
region
hr
interhel
ih
region
spike
domain
type
spike
protein
access
number
use
viral
antigen
virusspecif
cell
prolifer
assay
tabl
peptid
sigmaaldrich
synthes
fragment
overlap
amino
acid
lyophil
peptid
dissolv
dimethyl
sulfoxid
dmso
pool
approxim
concentr
mgml
store
gener
wholekil
viru
wkv
antigen
fipvucd
viru
stock
prepar
infect
feli
catu
whole
cell
atcc
cultur
viru
precipit
cultur
supernat
use
polyethylen
glycol
peg
high
speed
centrifug
inactiv
ultraviolet
uv
irradi
min
western
blot
infect
assay
use
cell
perform
confirm
presenc
viru
particl
viru
inactiv
wkv
prepar
respect
virusspecif
cell
prolifer
respons
pbmc
lnmc
isol
fipvinocul
cat
uninfect
control
assess
use
commerci
kit
base
bromodeoxyuridin
brdu
incorpor
brdu
flow
kit
bd
bioscienc
previous
describ
protocol
modif
briefli
freshli
isol
pbmc
lnmc
plate
cell
per
well
well
plate
standard
pbmc
media
without
cultur
rest
overnight
next
day
cell
stimul
wkv
overlap
peptid
pool
deriv
spike
ih
region
work
concentr
unstimul
cell
cultur
pbmc
media
without
serv
neg
control
cell
incub
brdu
h
prior
harvest
stain
brdu
incorpor
use
commerci
antibrdu
antibodi
label
allophycocyanin
apc
bd
bioscienc
accord
manufactur
instruct
cell
surfac
marker
cell
stain
antifelin
clone
southern
biotech
birmingham
al
conjug
pacif
blue
use
commerci
kit
molecular
probe
grand
island
ny
antifelin
clone
abd
serotec
assess
viabil
fixabl
aqua
stain
invitrogen
cell
fix
permeabil
accord
manufactur
instruct
next
stain
intracellular
express
use
antihuman
isothiocyan
fitc
clone
abd
serotec
brdu
incorpor
apclabel
antibrdu
antibodi
bd
bioscienc
data
acquir
use
lsrii
flow
cytomet
bd
bioscienc
event
collect
analyz
sampl
use
flowjo
softwar
treestar
inc
frequenc
viral
immunogenstimul
prolifer
adjust
subtract
frequenc
measur
unstimul
control
pbmc
prepar
sampl
yield
final
valu
frequenc
antigenspecif
cell
statist
analysi
compar
trend
differenti
blood
cell
count
determin
cat
primari
rechalleng
infect
time
base
linear
mix
effect
regress
model
use
random
effect
subject
account
repeat
measur
r
kruskal
walli
test
use
compar
lymphocyt
cell
count
three
differ
diseas
outcom
primari
fipv
infect
graphpad
softwar
inc
san
diego
ca
pairwis
analysi
perform
compar
median
frequenc
prolifer
cell
stimul
viral
immunogen
use
mannwhitney
u
test
onetail
also
use
graphpad
prism
p
valu
consid
signific
nineteen
naiv
spf
cat
inocul
oronas
isol
monitor
ill
day
postinfect
fifteen
cat
succumb
fip
primari
infect
remain
four
cat
still
healthi
without
fever
clinic
sign
fip
end
studi
day
pi
design
fip
resist
survivor
median
surviv
cat
develop
fip
primari
infect
day
eleven
diseas
cat
manifest
effus
form
wet
fip
character
ascit
inflamm
intestin
serosa
develop
noneffus
dri
wetdri
form
character
granulomat
lesion
abdomin
organ
central
nervou
system
tissu
eight
cat
effus
fip
die
within
day
deem
rapid
progressor
tabl
three
cat
effus
fip
four
cat
noneffus
fip
surviv
past
day
design
slow
progressor
tabl
overal
experiment
infect
cat
classifi
rapid
progressor
slow
progressor
fip
resist
survivor
ten
cat
surviv
primari
infect
includ
four
survivor
cat
acut
infect
studi
challeng
fipv
isol
one
ten
cat
succumb
fip
within
three
week
rechalleng
tabl
importantli
remain
nine
cat
within
rechalleng
group
develop
fip
base
absenc
fipassoci
symptom
secondari
exposur
viru
differenti
blood
cell
count
cell
frequenc
examin
longitudin
follow
primari
secondari
infect
total
white
blood
cell
wbc
count
decreas
significantli
follow
primari
infect
p
compar
healthi
agematch
control
fig
declin
total
white
cell
acut
primari
infect
associ
declin
neutrophil
fig
rather
signific
decreas
total
lymphocyt
cell
count
compar
uninfect
control
p
p
respect
fig
howev
wbc
absolut
lymphocyt
cell
count
significantli
declin
survivor
cat
second
inocul
rechalleng
infect
fig
cd
interestingli
differ
magnitud
lymphocyt
cell
deplet
associ
diseas
cours
survivor
show
declin
similar
observ
rapid
slow
progressor
paramet
four
week
time
period
follow
primari
inocul
fig
signific
differ
either
lymphocyt
cell
count
observ
three
anim
group
stratifi
outcom
acut
primari
infect
base
analysi
kruskal
walli
test
conduct
week
antibodi
titer
rang
cat
develop
fip
except
two
cat
surviv
day
day
demonstr
termin
titer
respect
tabl
titer
rang
four
week
pi
observ
four
cat
develop
fip
primari
fipv
infect
interestingli
four
survivor
cat
acut
infect
group
demonstr
higher
antifipv
antibodi
time
rechalleng
tabl
compar
titer
observ
week
acut
infect
cat
tabl
suggest
persist
viral
antigen
exposur
despit
resist
develop
fip
survivor
cat
demonstr
fourfold
increas
antivir
antibodi
four
week
period
rechalleng
tabl
viru
detect
viru
load
blood
correl
develop
fip
base
viral
rna
concentr
cell
prolifer
respons
follow
specif
antigen
stimul
base
brdu
incorpor
assay
longitudin
compar
cat
rapid
diseas
slower
progress
fip
resist
fip
due
protocol
limit
blood
volum
sampl
infectionassoci
lymphopenia
antivir
cell
respons
assay
consist
avail
cat
everi
time
point
repres
scatter
plot
assay
cell
prolifer
follow
antigen
stimul
shown
fig
signific
differ
cell
prolif
respons
either
viral
immunogen
observ
week
viru
inocul
cat
either
succumb
resist
develop
fip
fig
comparison
cat
die
resist
diseas
follow
primari
infect
limit
low
number
survivor
n
number
surviv
cat
assay
time
point
similarli
three
rapid
progressor
test
four
week
pi
due
death
rapid
progressor
earlier
time
point
despit
limit
certain
trend
antivir
immun
respons
demonstr
three
group
cat
emerg
cell
respons
wkv
detect
frequent
slow
progressor
test
survivor
test
one
week
pi
compar
rapid
progressor
test
fig
two
week
pi
higher
proport
rapid
progressor
cat
show
rel
strong
cell
respons
wkv
wherea
slow
progressor
survivor
demonstr
detect
cell
respons
time
point
fig
contrast
detect
respons
wkv
cell
respons
viral
peptid
infrequ
time
point
group
proport
cat
show
detect
cell
respons
either
wkv
peptid
week
pi
low
neglig
three
group
cat
coincid
persist
cell
loss
peripher
blood
first
observ
week
pi
howev
four
week
pi
recoveri
antivir
cell
respons
includ
cell
observ
select
slow
progressor
survivor
fig
cell
respons
low
neglig
rapid
progressor
week
infect
except
one
cat
cohort
cat
surviv
previou
challeng
allow
examin
memori
antivir
cell
respons
induc
reexposur
pathogen
fipv
isol
comparison
respons
associ
primari
infect
fig
small
subset
survivor
cat
reveal
detect
baselin
cell
respons
peptid
fig
otherwis
circul
cell
respons
peptid
wkv
respons
wkv
low
neglig
prior
rechalleng
cell
prolifer
respons
viral
peptid
significantli
differ
primari
rechalleng
infect
week
p
p
p
higher
cell
respons
observ
rechalleng
survivor
cat
cell
respons
wkv
viral
peptid
also
higher
rechalleng
infect
week
p
p
respect
mention
signific
declin
circul
lymphocyt
cell
count
observ
primari
infect
like
impact
antivir
cell
respons
p
valu
consid
signific
blood
contrast
similar
declin
lymphocyt
cell
count
associ
rechalleng
infect
noteworthi
cat
within
primari
infect
group
show
respons
similar
highest
respond
rechalleng
group
week
time
point
tend
slow
progressor
survivor
cat
fig
fig
base
wide
rang
cell
respons
observ
rechalleng
infect
group
stratifi
two
cohort
base
time
previou
exposur
fig
cat
rechalleng
fipv
within
month
primari
infect
show
greater
cell
respons
one
week
rechalleng
compar
cat
infect
one
year
rechalleng
fig
howev
observ
signific
cell
respons
wkv
p
cell
respons
compar
group
cat
week
rechalleng
infect
regardless
time
durat
primari
rechalleng
infect
importantli
cat
within
rechalleng
infect
group
demonstr
antivir
cell
respons
multipl
time
point
secondari
fipv
exposur
final
analysi
studi
compar
antivir
cell
respons
lnmc
harvest
mln
pln
pbmc
collect
time
euthanasia
due
onset
fip
pbmc
lnmc
similarli
assay
virusspecif
cell
prolifer
respons
viral
immunogen
although
data
pln
avail
cat
undergo
post
mortem
exam
longitudin
assess
lymph
node
cell
respons
time
infect
possibl
due
tempor
differ
diseas
cours
differ
cat
fip
assay
lymph
node
cell
respons
two
differ
cat
time
point
primari
infect
day
pi
also
avail
respons
rapid
slow
progressor
compar
lnmc
harvest
agematch
healthi
control
cat
serv
neg
control
antivir
cell
prolif
respons
vari
differ
tissu
within
individu
cat
differ
cat
differ
time
point
fig
howev
cell
respons
highest
magnitud
prolifer
cell
observ
mln
day
pi
blood
day
pi
test
either
wkv
viral
peptid
fig
cell
respons
peptid
usual
low
neglig
pbmc
except
pbmc
harvest
day
pi
two
rapid
progressor
cat
overal
higher
mln
cell
respons
wkv
observ
cat
develop
fip
day
primari
infect
suggest
associ
robust
cell
respons
particular
site
longer
surviv
although
differ
rapid
slow
progressor
statist
signific
also
import
frequent
lack
compar
magnitud
antivir
cell
respons
pln
mln
cat
suggest
pln
may
serv
surrog
site
assay
host
mln
respons
howev
trend
pln
cell
respons
wkv
greater
magnitud
observ
rapid
progressor
n
termin
time
point
compar
pln
respons
observ
slow
progressor
n
fig
although
differ
statist
signific
p
although
multipl
report
describ
immun
respons
associ
fipv
infect
immun
correl
protect
infect
anim
fatal
diseas
remain
poorli
understood
previou
studi
investig
antivir
cell
respons
induc
experiment
infect
either
fipv
limit
singl
timepoint
infect
provid
evid
support
role
cell
immun
resist
fip
report
describ
first
longitudin
studi
virusspecif
cell
respons
cat
experiment
infect
highli
pathogen
type
fipv
isol
aim
studi
identifi
possibl
antivir
cell
correl
diseas
outcom
acut
infect
rechalleng
fipresist
cat
fipv
isol
two
approach
use
character
correl
includ
comparison
cell
immun
respons
cat
either
exhibit
rapid
slow
progress
fip
develop
fip
primari
infect
second
approach
involv
comparison
cell
respons
cat
primari
infect
respons
elicit
rechalleng
exposur
cat
surviv
primari
fipv
challeng
reason
hypothesi
host
factor
respons
absenc
fip
would
emerg
circul
antivir
cell
respons
significantli
higher
magnitud
first
two
week
infect
howev
find
reveal
definit
correl
emerg
antivir
cell
respons
earli
stage
primari
infect
diseas
outcom
nevertheless
recoveri
antivir
cell
respons
later
time
point
primari
infect
emerg
antivir
cell
respons
fipresist
cat
second
exposur
fipv
suggest
cellular
immun
may
associ
level
control
fipv
infect
result
delay
absenc
diseas
progress
wkv
peptid
prove
capabl
evok
cell
prolif
respons
cat
experiment
infect
implement
valuabl
tool
longitudin
investig
antivir
cell
respons
primari
rechalleng
infect
limit
studi
includ
low
number
survivor
cat
primari
infect
assess
cell
respons
restrict
blood
earli
time
point
primari
infect
contrast
lymph
node
circul
cell
respons
compar
termin
time
point
cat
progress
diseas
comparison
respons
abdomin
lymphoid
tissu
earlier
time
point
infect
progressor
survivor
would
inform
base
typic
local
fipv
replic
abdomin
caviti
despit
limit
examin
antivir
cell
respons
blood
primari
infect
reveal
certain
trend
critic
observ
earlier
emerg
cell
respons
observ
slow
progressor
survivor
one
week
viru
inocul
contrast
delay
one
week
respons
emerg
cat
rapidli
progress
diseas
regardless
tempor
differ
earli
respons
magnitud
cell
respons
differ
significantli
cat
differ
diseas
outcom
first
three
week
earli
infect
almost
cat
show
neglig
respons
three
week
infect
howev
four
week
infect
proport
slow
progressor
survivor
distinguish
rapid
progressor
recoveri
antivir
cell
respons
collect
find
suggest
circul
antivir
cell
respons
earli
time
point
acut
infect
predict
diseas
outcom
yet
recoveri
circul
antivir
cell
respons
later
acut
infect
may
associ
delay
diseas
absenc
diseas
find
lend
support
widelyheld
hypothesi
fip
result
failur
cell
immun
also
suggest
undetermin
viru
host
interact
antivir
respons
critic
outcom
fip
robust
cell
respons
frequent
demonstr
mln
harvest
cat
number
shown
comparison
repres
p
valu
calcul
use
onetail
mannwhitney
u
test
graphpad
prism
p
valu
consid
signific
surviv
day
later
contrast
cell
respons
pln
harvest
earlier
time
point
primari
infect
tend
higher
magnitud
compar
pln
respons
observ
slow
progressor
also
plnassoci
cell
respons
frequent
match
mln
respons
host
particularli
cat
surviv
day
later
find
suggest
mln
may
repres
major
site
cellmedi
control
viru
replic
diseas
progress
fipv
respons
diseas
antivir
immun
find
may
surpris
base
previou
report
show
viru
replic
system
lymphoid
tissu
includ
mln
rel
absenc
detect
viru
pln
furthermor
previou
report
reveal
mildest
form
fip
diseas
limit
mln
cat
form
diseas
proceed
recoveri
suggest
role
antivir
immun
tissu
site
convers
dissemin
viru
infect
mln
site
within
host
associ
diseas
progress
strike
abnorm
observ
primari
fipv
infect
progress
declin
wbc
lymphopenia
cell
deplet
like
impact
host
respons
viru
infect
earli
phase
acut
primari
infect
new
observ
describ
report
natur
experiment
fipv
infect
cat
develop
fip
unexpect
find
observ
similar
profound
chang
cell
compart
cat
surviv
infect
outward
sign
diseas
primari
infect
compar
find
cell
deplet
also
report
cat
recov
without
fip
infect
pathogen
type
fipv
howev
find
also
report
group
one
survivor
one
rapid
progress
differ
studi
reveal
lymphopenia
demonstr
rapid
progressor
whether
differ
specif
fipv
isol
rout
inocul
intraperiton
inocul
studi
unknown
variabl
account
lymphopenia
cell
deplet
observ
studi
survivor
remain
determin
cell
deplet
observ
cat
regardless
subsequ
diseas
progress
provid
one
compel
explan
demis
detect
circul
antivir
cell
respons
three
week
primari
infect
cat
failur
character
cellular
immun
respons
associ
surviv
recent
experiment
fipv
infect
studi
group
reveal
sustain
immun
alway
maintain
upon
multipl
exposur
viru
suggest
distinct
antivir
cell
respons
may
confer
resist
fip
among
survivor
cat
rechalleng
survivor
cat
pathogen
fipv
describ
report
offer
import
opportun
examin
magnitud
cell
respons
secondari
exposur
fip
also
compar
respons
associ
primari
infect
moreov
rechalleng
studi
determin
whether
survivor
cat
would
capabl
maintain
resist
second
challeng
pathogen
result
reveal
nine
ten
cat
surviv
primari
infect
remain
resist
fip
secondari
exposur
infecti
regardless
span
time
primari
second
challeng
fipv
contrast
one
survivor
cat
subsequ
develop
fip
antivir
cell
respons
note
fipv
rechalleng
variabl
magnitud
particularli
one
week
pi
variabl
associ
durat
time
primari
secondari
infect
irrespect
variabl
cat
rechalleng
infect
associ
reappear
antivir
cell
respons
detect
cell
respons
observ
time
point
rechalleng
addit
rechalleng
infect
show
greater
antivir
cell
respons
multipl
time
point
fipv
rechalleng
includ
week
three
compar
primari
infect
respons
find
noteworthi
week
three
time
point
primari
infect
character
ablat
antivir
cell
respons
signific
cell
deplet
cat
includ
slow
progressor
survivor
furthermor
cat
surviv
earlier
infect
fipv
fail
develop
clinic
symptom
fip
also
demonstr
mild
lymphocyt
cell
deplet
rechalleng
pathogen
absenc
sever
lymphoid
deplet
clinic
sign
fip
survivor
cat
rechalleng
infect
along
detect
antivir
cell
respons
multipl
time
point
includ
three
week
pi
impli
role
cellular
immun
resist
fip
secondari
exposur
viru
note
survivor
cat
develop
fip
rechalleng
demonstr
antivir
cell
respons
earli
time
point
post
rechalleng
respons
absent
week
post
rechalleng
final
time
point
cat
persist
antivir
cell
respons
demonstr
human
patient
recov
sever
acut
respiratori
syndrom
sar
coronaviru
sarscov
howev
antivir
humor
respons
includ
neutral
antibodi
well
type
host
respons
must
also
consid
possibl
factor
resist
diseas
secondari
exposur
fipv
viremia
accur
predictor
diseas
outcom
observ
either
plasma
pbmc
approxim
cat
either
die
surviv
primari
infect
circul
viru
frequent
observ
two
week
pi
time
point
coincid
emerg
lymphocyt
cell
deplet
compar
well
result
experiment
studi
pathogen
type
fipv
viremia
typic
restrict
day
pi
detect
viral
rna
consist
detect
mesenter
lymph
node
post
mortem
cat
fip
confirm
tissu
consist
site
viru
replic
agreement
find
anoth
studi
measur
level
fipv
variou
tissu
high
level
viru
detect
diseas
tissu
particularli
omentum
mln
blood
contrast
survivor
cat
develop
detect
viremia
rechalleng
except
one
cat
develop
fip
secondari
exposur
test
posit
viral
rna
blood
mesenter
lymph
node
post
mortem
increas
fourfold
antivir
antibodi
titer
emerg
memori
cell
respons
observ
survivor
cat
four
week
rechalleng
suggest
possibl
level
viru
replic
result
second
exposur
nevertheless
control
host
respons
question
regard
site
persist
viru
replic
viru
elimin
cat
appar
resist
fip
infect
warrant
investig
includ
assess
multipl
tissu
viral
rna
describ
companion
pathogenesi
studi
viru
isol
nc
pedersen
et
al
taken
togeth
find
infect
studi
reveal
definit
immun
correl
resist
delay
progress
fip
acut
primari
infect
pathogen
type
fipv
except
recoveri
antivir
cell
respons
later
time
point
infect
slow
progressor
survivor
test
intrigu
find
antivir
cell
respons
circul
viru
load
magnitud
cell
deplet
immedi
primari
exposur
pathogen
fipv
appear
predict
diseas
resist
experiment
cohort
howev
cat
recov
fipvspecif
cell
respons
without
develop
fip
primari
infect
prove
capabl
resist
second
challeng
fipv
associ
emerg
recal
cell
respons
critic
virushost
interact
earli
infect
respons
resist
slow
progress
diseas
remain
unclear
experiment
primari
infect
studi
possibl
explan
includ
differ
magnitud
disrupt
innat
respons
specif
alter
innat
factor
report
sar
cov
fipv
virusinduc
inhibitori
macrophag
report
mous
model
sarscov
shown
contribut
reduc
dendrit
cell
activ
subsequ
delay
virusspecif
cell
respons
diseas
onset
inappropri
innat
respons
includ
unregul
proinflammatori
cytokin
respons
lead
either
cytokin
storm
report
sar
cov
overstimul
b
cell
possibl
lead
enhanc
antibodi
respons
describ
classic
wet
form
fip
similar
sar
overexpress
inflammatori
cytokin
includ
tumor
necrosi
factor
tnf
reduc
express
also
report
associ
develop
fip
product
proinflammatori
cytokin
fipvinfect
macrophag
also
implic
fipvassoci
lymphoenia
moreov
recent
report
reveal
target
antifelin
monoclon
antibodi
prevent
infect
cat
experiment
infect
fipv
proinflammatori
cytokin
antiviralrel
gene
viperin
also
observ
tissu
harvest
fcovinfect
cat
fip
addit
recent
report
focus
gene
express
profil
mesenter
periton
macrophag
harvest
cat
fip
reveal
express
pattern
recognit
receptor
includ
toll
nod
riglik
receptor
proapoptot
gene
gene
relat
differenti
macrophag
contrast
reduc
express
mch
class
ii
receptor
gene
lastli
role
host
antiinflammatori
factor
regulatori
cell
well
innat
factor
natur
killer
cell
factor
warrant
examin
base
recent
report
futur
studi
need
simultan
address
innat
adapt
respons
within
critic
tissu
site
earli
stage
infect
answer
critic
question
regard
mechan
recoveri
acut
pathogen
fipv
infect
key
find
studi
indic
circul
antivir
cell
respons
within
first
four
week
primari
infect
pathogen
fipv
isol
predict
diseas
outcom
furthermor
cat
develop
lymphopenia
cell
deplet
earli
fipv
infect
regardless
progress
resist
fip
find
suggest
role
cellular
immun
fipv
pathogenesi
recoveri
antivir
cell
respons
later
time
point
primari
infect
subset
cat
show
slow
progress
resist
diseas
cell
respons
measur
mln
harvest
post
mortem
robust
frequent
cat
show
slower
progress
fip
lastli
secondari
recal
antivir
cell
respons
observ
fipresist
cat
second
exposur
fipv
associ
resist
diseas
progress
well
absenc
lymphopenia
cell
deplet
overal
find
suggest
antivir
cell
immun
may
contribut
fipv
pathogenesi
